Jump to content

LUNGevityHunter

Members
  • Posts

    27
  • Joined

  • Last visited

Everything posted by LUNGevityHunter

  1. https://www.fda.gov/news-events/fda-voices/fda-seeks-patient-insight-call-applications-patient-engagement-collaborative Today, the FDA announced the call for applications for the next cohort of the Patient Engagement Collaborative (PEC). The PEC, established in 2018 in collaboration with the Clinical Trials Transformation InitiativeExternal Link Disclaimer (CTTI), is a group of patient organizations and individual representatives who discuss ways to enhance patient engagement. CTTI and the FDA collaborate to involve representatives with a variety of perspectives including patients, caregivers and representatives from diverse patient organizations. The PEC is run by the FDA’s Patient Affairs staff, which is dedicated to providing an inviting, welcoming and meaningful experience for patient communities to engage with the FDA. Representatives from the patient community who participate in the PEC include: Patients who have personal disease experience. Caregivers who have personal experience supporting someone with a health condition (e.g., a parent, child, partner, family member or friend). Representatives from patient groups who have direct or indirect disease experience. The PEC discusses topics such as: Creating new ways to collaborate with patient communities. Making patient engagement more systematic. Improving transparency through education and outreach. Enhancing communication between the FDA and patient communities.
  2. South Jersey hospital uses new robotic technology to detect lung cancer. Physicians will be able to sample small, previously unreachable, nodules https://www.njspotlight.com/video/south-jersey-hospital-uses-new-robotic-technology-to-detect-lung-cancer/
  3. COLUMBUS, Ohio – Ohio Gov. Mike DeWine today signed legislation that aims to raise awareness of the link between radon exposure and cancer risk by designating January as Radiation Awareness Month in Ohio. https://cancer.osu.edu/news/new-law-draws-awareness-to-link-between-radon-and-lung-cancer
  4. “LUNGevity Foundation Names NFN Scout, MA, PhD, as Community Champions Honoree. A well-regarded leader in health equity education, this month's honoree works to eliminate inequalities in cancer care within the LGBTQ community” https://www.prnewswire.com/news-releases/lungevity-foundation-names-nfn-scout-ma-phd-as-community-champions-honoree-301321400.html
  5. “The FDA has granted a breakthrough therapy designation from the FDA for patients with advanced non-small cell lung cancer with a KRASG12C mutation following prior systemic treatment.” https://www.targetedonc.com/view/fda-grants-breakthrough-therapy-designation-to-adagrasib-for-krasg12c-mutated-nsclc
  6. How the LUNGevity Foundation Is Empowering People with Late-Stage Lung Cancer: https://www.healthline.com/health/lung-cancer/hope-summit
  7. https://bluenotetherapeutics.com/post/cancer-distress-a-discussion-with-clinical-experts-from-mskcc/. A few weeks ago, a panel of patients and psycho-oncology experts from Memorial Sloan Kettering Cancer Center answered many questions regarding this topic. Questions like: What is the difference between cancer-related distress and normal, everyday stress? Does the treatment of cancer-related anxiety reduce a patient’s experience of physical pains that are associated with the disease? Has the stress level of cancer patients risen due to compromised immune systems and COVID? Is there such a thing as a stress roller-coaster that cancer patients experience? Is there a difference between fear of “progression of cancer” and “fear of recurrence”? How to ask for psycho-oncology help?
  8. TRIDENT-1 is enrolling participants in a Phase 2 multi-center study evaluating an investigational drug repotrectinib for the treatment of individuals with ROS1+ advanced non-small cell lung cancer (NSCLC) as well as individuals with NTRK+ advanced solid tumors. Patient Website link: http://trident1study.com Patient eBrochure link: https://online.flippingbook.com/view/462279568/
  9. FDA APPROVES LUMAKRASTM(SOTORASIB), THE FIRST AND ONLY TARGETED TREATMENT FOR PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER https://www.reuters.com/article/amgen-fda-lumakras-idUSL2N2ND2BA
  10. “Tecentriq improved disease-free survival by more than one-third in people with PD-L1-positive, resectable early-stage lung cancer, compared with best supportive careFirst and only cancer immunotherapy to show positive Phase III results in the adjuvant lung cancer setting. New adjuvant treatment options are urgently needed in early lung cancer to help the approximately 50% of people who currently experience recurrence following surgery”
  11. https://www.wtkr.com/news/new-national-campaign-aims-to-fight-against-lung-cancer
  12. https://www.targetedonc.com/view/capmatinib-addresses-subset-of-met-amplified-non-small-cell-lung-cancer
  13. https://www.medicalnewstoday.com/articles/how-it-works-immunotherapy-for-lung-cancer
  14. “No Small Challenge: Emerging Therapies in Small Cell Lung Cancer” https://www.curetoday.com/view/no-small-challenge-emerging-therapies-in-small-cell-lung-cancer
  15. Thank you, Tim. Congratulations on NED! You may have more options, if/when needed. There are many ongoing clinical trials testing new lung cancer treatments, including targeted therapies, chemotherapy, radiation therapy, and immunotherapy, alone and in combination. Our partners at EmergingMed offer a clinical trial navigation service- connect with them at 877-769-4834
  16. “As part of its “Speaking Out” video series, CURE® spoke with Katie Brown from LUNGevity about challenges that have arisen from the COVID-19 pandemic — including delays in screening — and resources to help patients through these trying times.” https://www.curetoday.com/view/quelling-covid-19-and-cancer-fears
  17. NSCLC occurs in 80-85% of lung cancer cases and despite treatment advances, we need to discover more options for people with advanced lung cancer. Genetic testing has become increasingly important in clinical research and potential treatments for NSCLC. Recently, a BRAF cell mutation has been identified as a potential target in investigational therapies. Pfizer is currently conducting the Landscape 1011 Study, a clinical research study exploring the effects of different study drugs given in combination for advanced non-small cell lung cancer. This study may be an option for men or women who are: 18 years or older Have advanced (stage 3b or 4) non-small cell lung cancer Have a BRAF mutation (if you aren’t sure if you have the BRAF mutation, please ask your physician) Are fully or reasonably active Assistance with travel support to and from appointments may be offered. Learn more, now! To see if you may qualify, please contact us at: 1-800-718-1021 or http://[email protected] Participating in the Landscape 1011 Study may help contribute to the development of potential therapies for advanced lung cancer.”
  18. You've gotten some great responses above- I just wanted to post here to welcome you and let you know you are not alone. Keep posting- H
  19. https://www.businesswire.com/news/home/20210329005097/en/DESTINY-Lung02-Phase-2-Trial-of-ENHERTU®-Initiated-in-Patients-with-HER2-Mutated-Metastatic-Non-Small-Cell-Lung-Cancer
  20. https://www.gene.com/media/press-releases/14901/2021-03-21/pivotal-phase-iii-study-shows-genentechs Sunday, Mar 21, 2021 Pivotal Phase III Study Shows Genentech’s Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease Returning First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care Treating lung cancer early, before it has spread, may help prevent the disease from returning and therefore provide the best opportunity for a cure Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration and the European Medicines Agency, and presented at an upcoming medical meeting South San Francisco, CA -- March 21, 2021 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower010 study evaluating Tecentriq ® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant improvement in DFS as adjuvant therapy following surgery and chemotherapy in all randomized Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS in the overall intent-to-treat (ITT) population, which at the time of analysis did not cross the threshold, and overall survival (OS) data, which were immature at the time of interim analysis. Safety for Tecentriq was consistent with its known safety profile and no new safety signals were identified. Results from the IMpower010 study will be presented at an upcoming medical meeting and submitted to health authorities globally, including the U.S. Food and Drug Administration and the European Medicines Agency. “With these landmark results, Tecentriq has become the first cancer immunotherapy to help many people with resectable early lung cancer live longer without their cancer returning," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We’re excited by the clinical benefit adjuvant Tecentriq may bring to lung cancer patients, particularly in the PD-L1-positive population. We will submit these data to regulatory authorities as soon as possible.” Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with five currently approved indications in the U.S. It was the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide (chemotherapy), and also has four approved indications in NSCLC as either a single agent or in combination with targeted therapies and/or chemotherapies. Tecentriq is available in three dosing options, providing the flexibility to choose administration every two, three or four weeks. Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across different lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant and neoadjuvant settings across various tumor types. About the IMpower010 study IMpower010 is a Phase III, global, multicenter, open-label, randomized study evaluating the efficacy and safety of Tecentriq compared with BSC, in participants with Stage IB-IIIA NSCLC (UICC 7th edition), following surgical resection and up to 4 cycles of adjuvant cisplatin-based chemotherapy. The study randomized 1,005 people with a ratio of 1:1 to receive either at most 16 cycles of Tecentriq or BSC. The primary endpoint is investigator-determined DFS in the PD-L1-positive Stage II-IIIA, all randomized Stage II-IIIA and ITT Stage IB-IIIA populations. Key secondary endpoints include OS in the overall study population, ITT Stage IB-IIIA NSCLC. About lung cancer According to the American Cancer Society, it is estimated that more than 235,000 Americans will be diagnosed with lung cancer in 2021, and NSCLC accounts for 80-85% of all lung cancers. Today, about half of all people with early lung cancer still experience a cancer recurrence following surgery. Treating lung cancer early, before it has spread, may help prevent the disease from returning and provide people with the best opportunity for a cure. About Tecentriq ® (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq U.S. Indications Tecentriq is a prescription medicine used to treat adults with: A type of lung cancer called non-small cell lung cancer (NSCLC). Tecentriq may be used alone as their first treatment when their lung cancer: has spread or grown, and their cancer tests positive for “high PD-L1”, and their tumor does not have an abnormal “EGFR” or “ALK” gene Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as their first treatment when their lung cancer: has spread or grown, and is a type called “non-squamous NSCLC,” and their tumor does not have an abnormal “EGFR” or “ALK” gene Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as their first treatment when their lung cancer: has spread or grown, and is a type called “non-squamous NSCLC,” and their tumor does not have an abnormal “EGFR” or “ALK” gene Tecentriq may also be used when their lung cancer: has spread or grown, and they have tried chemotherapy that contains platinum, and it did not work or is no longer working if their tumor has an abnormal “EGFR” or “ALK” gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working A type of lung cancer called small cell lung cancer (SCLC). Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as their first treatment when their lung cancer: is a type called “extensive-stage small cell lung cancer,” which means that it has spread or grown It is not known if Tecentriq is safe and effective in children. Important Safety Information What is the most important information about Tecentriq? Tecentriq can cause the immune system to attack normal organs and tissues in any area of the body and can affect the way they work. These problems can sometimes become severe or life threatening and can lead to death. Patients can have more than one of these problems at the same time. These problems may happen anytime during their treatment or even after their treatment has ended. Patients should call or see their healthcare provider right away if they develop any new or worse signs or symptoms, including: Lung problems cough shortness of breath chest pain Intestinal problems diarrhea (loose stools) or more frequent bowel movements than usual stools that are black, tarry, sticky, or have blood or mucus severe stomach-area (abdomen) pain or tenderness Liver problems yellowing of the skin or the whites of the eyes severe nausea or vomiting pain on the right side of their stomach area (abdomen) dark urine (tea colored) bleeding or bruising more easily than normal Hormone gland problems headaches that will not go away or unusual headaches eye sensitivity to light eye problems rapid heartbeat increased sweating extreme tiredness weight gain or weight loss feeling more hungry or thirsty than usual urinating more often than usual hair loss feeling cold constipation their voice gets deeper dizziness or fainting changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness Kidney problems decrease in their amount of urine blood in their urine swelling of their ankles loss of appetite Skin problems rash itching skin blistering or peeling painful sores or ulcers in mouth or nose, throat, or genital area fever or flu-like symptoms swollen lymph nodes Problems can also happen in other organs. These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq. Patients should call or see their healthcare provider right away for any new or worse signs or symptoms, including: Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight Persistent or severe muscle pain or weakness, muscle cramps Low red blood cells, bruising Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: chills or shaking itching or rash flushing shortness of breath or wheezing dizziness feeling like passing out fever back or neck pain Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if patients undergo transplantation either before or after being treated with Tecentriq. A healthcare provider will monitor for these complications. Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider will check patients for these problems during their treatment with Tecentriq. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may also need to delay or completely stop treatment with Tecentriq if patients have severe side effects. Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they: have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus have received an organ transplant have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) have received radiation treatment to their chest area have a condition that affects their nervous system, such as myasthenia gravis or Guillain-Barré syndrome are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant: A healthcare provider should do a pregnancy test before they start treatment with Tecentriq They should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into the breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of Tecentriq when used alone include: feeling tired or weak nausea cough shortness of breath decreased appetite The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include: feeling tired or weak nausea hair loss constipation diarrhea decreased appetite Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility. These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq. Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at 1-888-835-2555. Please see http://www.Tecentriq.com for full Prescribing Information and additional Important Safety Information. About Genentech in cancer immunotherapy Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system. In addition to Genentech’s approved PD-L1 checkpoint inhibitor, the company’s broad cancer immunotherapy pipeline includes other checkpoint inhibitors, individualized neoantigen therapies and T cell bispecific antibodies. For more information visit http://www.gene.com/cancer-immunotherapy. About Genentech in lung cancer Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
  21. LUNGevity and Family Reach Announce New Partnership to Help Lung Cancer Patients Financially Plan for their Care The partnership will provide patients and their families financial education, navigation, planning, and more https://www.prnewswire.com/news-releases/lungevity-and-family-reach-announce-new-partnership-to-help-lung-cancer-patients-financially-plan-for-their-care-301250321.html
  22. Lung cancer diagnosis and treatment should be “stigma-free” Navy Veteran: “Patients should be treated with empathy“ https://blogs.va.gov/VAntage/86102/lung-cancer-diagnosis-treatment-stigma-free/
  23. “Used with CT screening, liquid biopsies can help oncologists determine whether to move forward with more invasive procedures.” https://chicagohealthonline.com/liquid-biopsies-may-help-identify-lung-cancer/
  24. “The Denver chapter of Golfers Against Cancer in February named University of Colorado (CU) Cancer Center researchers Matthew Sikora, PhD, Jamie Studts, PhD, and Jenna Sopfe, MD, as the beneficiaries of three $50,000 grants for cancer research and clinical trials.” https://www.eurekalert.org/pub_releases/2021-03/uoca-gac031521.php?fbclid=IwAR2Wh0tQvHUAJQuDOocLTVoWYCyk9pI7iKGRetsPMpEPi9MdgBQ1RnmirKE#.YFI0vnEH_uA.facebook
×
×
  • Create New...